CN108498698A - Treat the Chinese medicine composition of retinal pigment degeneration - Google Patents
Treat the Chinese medicine composition of retinal pigment degeneration Download PDFInfo
- Publication number
- CN108498698A CN108498698A CN201810605467.7A CN201810605467A CN108498698A CN 108498698 A CN108498698 A CN 108498698A CN 201810605467 A CN201810605467 A CN 201810605467A CN 108498698 A CN108498698 A CN 108498698A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- retinal pigment
- medicine composition
- radix
- pigment degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to tcm fields, disclose a kind of Chinese medicine composition for treating retinal pigment degeneration, including following component：15 20g of prepared rehmannia root, 10 15g of sealwort, 10 20g of matrimony vine, 10 15g of Semen Cuscutae, 10 15g of Fructus Corni, 10 20g of Chinese yam rhizome, 15 20g of Poria cocos, 10 15g of Paper mulberry Fruit, 10 15g of the root bark of tree peony, 10 15g of Radix Notoginseng, 10 20g of Radix Salviae Miltiorrhizae, 10 15g of the root of bidentate achyranthes, 10 20g of Radix Angelicae Sinensis, 10 15g of the shell of seaear, 10 15g of Rhizoma Chuanxiong, 10 15g of Rhizoma Et Radix Notopterygii, 10 15g of grass-leaved sweetflag.Pilule is made by Modern preparations technique, bottled spare, every bottle of 120g, each 10g, 3 times a day, warm water delivery service after meal.The present invention is significantly improved to the therapeutic effect of RP relative to drug in the market.
Description
Technical field
The present invention relates to tcm fields, and in particular to a kind of Chinese medicine composition for treating retinal pigment degeneration.
Background technology
Retinal pigment degeneration (Retinitis pigmentosa, RP) is one group on progressive photosensory cell and pigment
Skin function lose be coexpress retinal hereditary disease, its main clinical characteristics be yctalopia, progressive defect of visual field,
The feature on eyeground sexually revises and the exception of electroculogram.According to different genetic methods, retinal pigment degeneration can be divided into
Autosomal dominant, autosomal recessive, chromosome linkage and a small number of dual-gene mutation heredity and mitochondrial inheritance.Retina
Pigmental degeneration countries in the world incidence between 1/5000-1/3000, be that most common heredity endangers eyeground blinding
One of eye disease.Most of patients with retinitis pigmentosa are hidden in adolescence morbidity, morbidity, non-evident sympton sign,
The lesion early stage visual field is that the annular visual field only remains the central tubular visual field, seriously then gradually to center and circumferential expansion to late period
Patients ' life quality is influenced, if being not treated in time, for the state of an illness by sustainable development, pain is self-evident.Retinal pigment degeneration is again
It is referred to as " not being the cancer of cancer ".Therefore, urgent clinical needs can treat the drug of RP.
Retinal pigment degeneration is classified as the scope of " high wind cataract " by Chinese medicine, and thinks that native endowment deficiency is retinal color
The main reason for element denaturation occurs, alternatively, it is also possible to be lost by kidney-yang deficiency, the Yang-function insufficiency of kidneyzang；Both liver and kidney deficiency, asthenia of essence and blood, negative and positive are not
Ji, yang-energy cannot be to use；Weakness of the spleen and the stomach, lucid yang failing to raise is contained on turbid yin, and sun is unevident bright；Insufficiency of vital energy and blood etc. causes.Therefore successive dynasties doctor
Family mostly sets about from void, mostly treats retinal pigment degeneration from spleen liver kidney, produces effects still.
Chinese patent application publication No. is 104606435 A of CN, and publication date is that the application case of 2015.05.13 discloses one
Kind treats drug of retinal pigment degeneration and preparation method thereof, and each component and its mass parts ratio of the drug are：Radix rehmanniae preparata,
The root bark of tree peony, Yun Ling, Chinese yam, rhizoma alismatis, cornus, Chinese cassia tree, monkshood, bat's faces, rhizoma atractylodis are 1-3 parts each, are prepared into Chinese medicine and take.This drug
Tanning drug is needed before taking, it is more time-consuming.
Clinically lack the Chinese patent drug of effectively treatment retinal pigment degeneration at present.It is an object of the invention to overcome at present
The poor deficiency of retinal pigment degeneration curative effect is treated, a kind of pure Chinese medicine drug composition for treating retinal pigment degeneration is provided.
Invention content
The purpose of the invention is to overcome it is of the existing technology shortage effectively treatment retinal pigment degeneration at
Medicine problem, provides a kind of pure Chinese medicine formula for treating retinal pigment degeneration, which has advantages of perfect compatibility, therapeutic effect
It is good, it is without side-effects to human body, it tonifies the liver and kidney, effect promoting blood circulation and removing blood stasis.
To achieve the goals above, the present invention provides a kind of Chinese medicine composition for treating retinal pigment degeneration, including such as
Lower component：
Preferably, a kind of Chinese medicine composition for treating retinal pigment degeneration, including following component：
The Chinese medicine composition key component is：Prepared rehmannia root, sealwort, matrimony vine, Chinese yam rhizome and Radix Notoginseng.
Pilule is made by Modern preparations technique in the Chinese medicine composition, bottled spare, every bottle of 120g, each 10g, daily
3 times, warm water delivery service after meal.
The pharmacological action of this Chinese medicine composition is：For the Etiological of RP, from void start with prepared rehmannia root, matrimony vine, Tu
Son, tonifies the liver and kidney at sealwort, achievees the purpose that benefit is Kidney-Yin, promoting vital essence and blood genernation, fills out marrow, anti-aging, except blurred vision；Radix Notoginseng, Rhizoma Chuanxiong promoting blood circulationization
The stasis of blood；The shell of seaear, the root of bidentate achyranthes are calming the liver；Rhizoma Et Radix Notopterygii pungent can dissipate anti-stagnant and carry medicine uplink；Grass-leaved sweetflag, which has one's ideas straightened out to declare, to be led to, and is dredged in profit mesh
Xuan Fu.All medicines share, play altogether tonify the liver and kidney, work(promoting blood circulation and removing blood stasis.
Through the above technical solutions, following advantageous effect can be obtained：
1. the Chinese medicine composition, using natural edible-plant medicine as raw material, each component meets national politics and law regulation.Using each
The comprehensive function of taste Chinese medicine can significantly improve eyesight in 12 weeks, and retinal pigment degeneration symptom can be obviously improved by continuing medication, and
This drug has no toxic and side effect to human body, no tolerance.
2. pilule is made in the Chinese medicine composition of the present invention, bottled spare, pill is taken out after meal, warm water delivery service, daily 3
It is secondary, it does not need patient and the time is spent to boil Chinese medicine, it is convenient and time-saving, and also this drug is pill, facilitates taking for patient, reduces and suffers from
Person take medicine during pain.
3. the Chinese medicine composition of the present invention is significantly improved to the therapeutic effect of RP relative to drug in the market.
4. the present invention Chinese medicine composition have tonify the liver and kidney, effect promoting blood circulation and removing blood stasis.
Specific implementation mode
The endpoint of disclosed range and any value are not limited to the accurate range or value herein, these ranges or
Value should be understood as comprising the value close to these ranges or value.For numberical range, between the endpoint value of each range, respectively
It can be combined with each other between the endpoint value of a range and individual point value, and individually between point value and obtain one or more
New numberical range, these numberical ranges should be considered as specific open herein.
The present invention will be described in detail by way of examples below.
Embodiment 1
A kind of Chinese medicine composition for treating retinal pigment degeneration, component include：Prepared rehmannia root 15-20g, sealwort 10-15g,
Matrimony vine 10-20g, Semen Cuscutae 10-15g, Fructus Corni 10-15g, Chinese yam rhizome 10-20g, Poria cocos 15-20g, Paper mulberry Fruit 10-15g, pellet
Skin 10-15g, Radix Notoginseng 10-15g, Radix Salviae Miltiorrhizae 10-20g, root of bidentate achyranthes 10-15g, Radix Angelicae Sinensis 10-20g, shell of seaear 10-15g, Rhizoma Chuanxiong 10-15g,
Rhizoma Et Radix Notopterygii 10-15g, grass-leaved sweetflag 10-15g.The key component of this drug is：Prepared rehmannia root, sealwort, matrimony vine, Chinese yam rhizome and Radix Notoginseng.
Embodiment 2
A kind of Chinese medicine composition for treating retinal pigment degeneration, component include：Prepared rehmannia root 15g, sealwort 10g, matrimony vine
15g, Semen Cuscutae 10g, Fructus Corni 10g, Chinese yam rhizome 10g, Poria cocos 15g, Paper mulberry Fruit 10g, root bark of tree peony 10g, Radix Notoginseng 10g, Radix Salviae Miltiorrhizae 15g,
Root of bidentate achyranthes 10g, Radix Angelicae Sinensis 15g, shell of seaear 10g, Rhizoma Chuanxiong 15g, Rhizoma Et Radix Notopterygii 10g, grass-leaved sweetflag 10g.
Pilule is made by Modern preparations technique in said components, bottled spare, every bottle of 120g, each 10g, 3 times a day,
Warm water delivery service after meal.
To show that therapeutic effect of the above-mentioned Chinese medicine composition to RP, the present invention select medical history, the state of an illness, age and gender and original
The comparable case of therapy carries out clinical therapeutic efficacy comparison using Chinese medicine composition of the present invention：
Case 1：Old primary pigmentary degeneration of retina
Poplar, man, 56 years old, peasant visited medical on November 18th, 2010.Patient's Binocular vison force difference, handicapped 2
Nian Duo starts night for about 9 years old or so regarding object not as good as ordinary person, and vision range becomes narrow gradually after about 20 years old, collides periphery object sometimes
Part, central vision is also faded after about 40 years old, handicapped after about 50 years old, can only be in known place activity.Patient
Deny that parent has similar medical history, but is cross-cousin marriage cigarette.
It looks into：Eyesight：The right side 0.01, a left side 0.02.Intraocular pressure is normal.Right eye refracting media is still transparent, and optic disk color is wax yellow, clear-cut margin.
View retinal vasculature generally attenuates, and artery becomes apparent from.Retina is in steel gray tone, and retina is covered with many irregular osteocytes
Sample pigment is located on blood vessel or under it.Macula area color is gloomy, and reflective disappearance is returned at center.Left eye bottom is roughly the same with right eye bottom.
Because eyesight is too poor, inconvenience checks the visual field.Between feeling or dizzy tinnitus, soreness of waist and knee.Red tongue body, no tongue, arteries and veins are slow slightly thin.It is diagnosed as
Eyes primary pigmentary degeneration of retina.It is liver kidney void, asthenia of essence and blood, eyeground channels according to fundus Oculi Manifestations and tongue vein situation
The stasis of blood is stagnant, loses day caused by supporting.Belong to the deficiency of liver-yin and kidney-yin and has blood trouble concurrently.It controls preferably nourishing liver and kidney simultaneous with promoting blood circulation and removing blood stasis.It is each to take this pill
10g, day 3 times take 3 months and check.
Two examine：Conscious medicine has no adverse reaction, and eyesight slightly improves, the right side 0.03, a left side 0.04.Eyeground is without improvement.Continue to take 3
A month.
Case 2：Deaf-mute's retinal pigment degeneration
It is deep certain, man 32 years old, is in unemployed, visits on March 10th, 2007 medical.Household tells in generation：Patient from small deaf and dumb,
There is yctalopia within 10 years old or so, later eyesight is faded, and vision range becomes narrow gradually, until current blurring of vision.Intellectual development is just
Often, good in school for deaf-mutes's school grade.Limb development no abnormality seen.Give birth to a girl after marriage, 4 years old, currently without yctalopia, eyeground without
It is abnormal.Its parent non-near parent's wedding end, also without similar medical history.
It looks into：Eyesight：The right side 0.5, a left side 0.4.Add mirror helpless.Intraocular pressure is normal.Expand pupil inspection：Right eye bottom refracting media has no muddy.
Optic disk colour band is wax yellow, and edge is clear.Retinal vessel attenuates, especially apparent with artery.Retina is in cinerous, is abound with bone thereon
Cell sample pigment, some is on blood vessel, and some is under blood vessel.Macula area structure owes clear, and central fovea is reflective to may be seen indistinctly.It is left
Eyeground is substantially similar to right eye.Peripheral visual field is in apparent concentric contraction, up between 15 ° -25 °.Whole body no conscious sympton.Tongue
Matter is light red, and tongue is thin white, and arteries and veins is slow.It is diagnosed as retina of both eyes pigmental degeneration.It is liver-kidney deficiency, asthenia of essence and blood, the channels stasis of blood is stagnant, and mesh loses
It supports, so that God Light day subtracts.It is stagnant that card category liver virtual loss has the stasis of blood concurrently.It controls and preferably tonifies the liver and kidney, and with stagnation resolvation.With this pill, each 10g,
3 times a day, it takes 3 months.
Two examine：Eyesight improves, the right side 0.7, a left side 0.6.The visual field expands 10 ° or so.It advises and continues with medicine-feeding 3 months.
Clinical sample
Once primary pigmentary degeneration of retina 35 70 eyes of patient were treated with this pill, the age is 11 years old minimum, maximum 65
It is year, 39.8 years old average；24 34 eyes of age-related macular degeneration (moist denaturation 66, dryness are denaturalized 18 28), the age is most
It is 50 years old small, it is 77 years old maximum, it is 65.34 years old average.Using this pill, each 10g, 3 times a day, warm water delivery service, takes 3 after meal
Month.
Contrast sample
34 68 eyes of control group primary pigmentary degeneration of retina patient, the age is 10 years old minimum, 66 years old maximum, average
38.9 years old；23 34 eyes of age-related macular degeneration (moist denaturation 56, dryness are denaturalized 18 28), the age is 51 years old minimum,
It is 76 years old maximum, it is 64.8 years old average.Control group Qiju Dihuang Wan, each 10g, 3 times a day, warm water delivery service, takes 3 after meal
Month.
1 clinical sample of table and the comparison of the total effective rate of contrast sample
| Clinical sample | Contrast sample | The significance of difference (P) | |
| Symptom total effective rate | 83.3% | 84.9% | >0.05 |
| Eyesight curative effect total effective rate | 78.8% | 34.3% | <0.05 |
| Visual field curative effect total effective rate | 74.7% | 33.7% | <0.05 |
By the result of table 1 can be seen that clinical sample that Chinese medicine composition using the present invention is treated relative to
Contrast sample has the effect of significantly improving eyesight, improves the visual field and blood index.
The preferred embodiment of the present invention has been described above in detail, and still, the present invention is not limited thereto.In the skill of the present invention
In art conception range, technical scheme of the present invention can be carried out a variety of simple variants, including each technical characteristic with it is any its
Its suitable method is combined, and it should also be regarded as the disclosure of the present invention for these simple variants and combination, belongs to
Protection scope of the present invention.
Claims (2)
1. a kind of Chinese medicine composition for treating retinal pigment degeneration, which is characterized in that including following component：
2. treating the Chinese medicine composition of retinal pigment degeneration according to claim 1, which is characterized in that including such as the following group
Point：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810605467.7A CN108498698A (en) | 2018-06-13 | 2018-06-13 | Treat the Chinese medicine composition of retinal pigment degeneration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810605467.7A CN108498698A (en) | 2018-06-13 | 2018-06-13 | Treat the Chinese medicine composition of retinal pigment degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108498698A true CN108498698A (en) | 2018-09-07 |
Family
ID=63403231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810605467.7A Pending CN108498698A (en) | 2018-06-13 | 2018-06-13 | Treat the Chinese medicine composition of retinal pigment degeneration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108498698A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112451513A (en) * | 2020-11-02 | 2021-03-09 | 杭州利孚泰生物科技有限公司 | Application of salvianolic acid A in preparation of medicine for preventing and treating visible retina injury |
| CN114209761A (en) * | 2021-10-12 | 2022-03-22 | 中日友好医院 | Traditional Chinese medicine composition for treating retinitis pigmentosa |
| EP3876712A4 (en) * | 2018-11-14 | 2022-05-18 | Zhuhai Qiwei Bio-technology Ltd. | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468068A (en) * | 2007-12-28 | 2009-07-01 | 上海润知生物科技有限公司 | Chinese medicinal composition for improving cyclic metabolism of retina and preparation method thereof |
| CN106728705A (en) * | 2017-03-19 | 2017-05-31 | 郝振昌 | It is a kind of to treat medicine of retinal pigment degeneration and preparation method thereof |
-
2018
- 2018-06-13 CN CN201810605467.7A patent/CN108498698A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468068A (en) * | 2007-12-28 | 2009-07-01 | 上海润知生物科技有限公司 | Chinese medicinal composition for improving cyclic metabolism of retina and preparation method thereof |
| CN106728705A (en) * | 2017-03-19 | 2017-05-31 | 郝振昌 | It is a kind of to treat medicine of retinal pigment degeneration and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李卫平等: "RP-HPLC测定滋阴明目片中马钱苷含量", 《中国实验方剂学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3876712A4 (en) * | 2018-11-14 | 2022-05-18 | Zhuhai Qiwei Bio-technology Ltd. | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
| CN112451513A (en) * | 2020-11-02 | 2021-03-09 | 杭州利孚泰生物科技有限公司 | Application of salvianolic acid A in preparation of medicine for preventing and treating visible retina injury |
| CN114209761A (en) * | 2021-10-12 | 2022-03-22 | 中日友好医院 | Traditional Chinese medicine composition for treating retinitis pigmentosa |
| CN114209761B (en) * | 2021-10-12 | 2023-03-17 | 中日友好医院 | Traditional Chinese medicine composition for treating retinitis pigmentosa |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101601828B (en) | Eyesight-recovering traditional Chinese medicine for treating optic neuritis and optic nerve atrophy | |
| CN108498698A (en) | Treat the Chinese medicine composition of retinal pigment degeneration | |
| CN104435763A (en) | Medicine for treating oculopathy | |
| CN102600386B (en) | Chinese herba preparation for treating eye inflammation and preparation method of Chinese herba preparation | |
| CN103735835B (en) | A kind of Chinese medicine preparation for the treatment of young person with greying hair and preparation method thereof | |
| CN104069364A (en) | Traditional Chinese medicine for treating optic atrophy | |
| CN111035748A (en) | Traditional Chinese medicine composition for improving myopia, external application preparation for improving myopia and eye patch for improving myopia | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| CN112121104B (en) | Traditional Chinese medicine composition for relieving asthenopia and preventing and treating myopia | |
| CN110448618A (en) | A kind of Chinese medicine preparation and preparation method thereof for treating eyesight | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN112294963A (en) | Pharmaceutical composition for treating age-related macular degeneration | |
| CN102210841A (en) | Chinese medicinal preparation for treating central serous retinopathy | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN108498615A (en) | A kind of Chinese herb medicine eye health-care patch and preparation method thereof improving eyes based on nitric oxide principle | |
| CN109663100A (en) | A kind of Chinese medicine composition and its preparation method and application for treating optic neuritis | |
| CN117883524B (en) | Liver nourishing and eyesight improving composition and preparation method and application thereof | |
| CN102895559A (en) | Chinese medicinal preparation for treating central serous chorioretinopathy | |
| CN115645483B (en) | Application of composition in preparation of medicine for treating dry age-related macular degeneration | |
| CN115737778B (en) | Traditional Chinese medicine preparation with pressure regulating effect | |
| CN106491730A (en) | A kind of treat Chinese medicine composition of glaucoma and preparation method thereof | |
| CN106581221A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN106166234A (en) | One treats cataractous Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180907 |
|
| RJ01 | Rejection of invention patent application after publication |